3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
7
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
2
Refractory or Relapsed Solid Tumors
1
Prostatic Neoplasms, Castration-Resistant
1
Non-metastatic Castration-resistant Prostate Cancer
1
Metastatic Castration-resistant Prostate Neoplasms
1
Metastatic Castration-resistant Prostate Cancer
1
Bulbo-Spinal Atrophy, X-Linked
1
Biochemically Recurrent Prostate Cancer
1
Adenocarcinoma
1
Interventions
Oxaliplatin
3
Leucovorin
3
Fluorouracil
3
Capecitabine
3
zolbetuximab
2
trastuzumab deruxtecan
2
pembrolizumab
2
Ramucirumab
2
Paclitaxel
2
repotrectinib
1
lenvatinib
1
fludarabine
1
enzalutamide
1
durvalumab
1
darolutamide
1
aldesleukin
1
Vinorelbine
1
Radiosurgery
1
Radiation
1
Prednisone
1
Prednisolone
1
Positron-Emission Tomography
1
Pemetrexed
1
PF06821497
1
Nivolumab
1
Negative-Pressure Wound Therapy
1
Microscopy, Confocal
1
MORAb-202
1
Irinotecan
1
Immunotherapy
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
darolutamide
×
30 days
×
Clear all
NCT07617272
2026-06-01
PARIS-BIO
Region Stockholm
Phase 2
Recruiting
100 enrolled